ABI-013

ABI-013 (also known as nab-CY196) is a solvent-free, nanoparticle albumin-bound (nab) formulation of CY196, a novel docetaxel analog. Developed using proprietary nab-technology originally by Abraxis BioScience (later acquired by Celgene and subsequently Bristol Myers Squibb), ABI-013 is designed to improve the therapeutic index of docetaxel-based chemotherapy by avoiding systemic toxicities associated with conventional solvent vehicles (such as polysorbate 80 and ethanol). As a microtubule stabilizer, the active taxane moiety binds to tubulin, inhibiting microtubule depolymerization and arresting cell division. Preclinical studies have demonstrated that ABI-013 possesses superior antitumor activity and a favorable safety profile compared to docetaxel in xenograft models of breast, colorectal, and non-small cell lung cancers.

Other names

(αR, βS)-β-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-(hexanoyloxy)benzenepropanoic acid (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 6, 11-trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodecal[3, 4]benz[1, 2-b]oxet-9-yl esteralbumin-bound docetaxel analognab-docetaxel analognab-novel taxanenanoparticle albumin-bound docetaxel analog